Fig. 5From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?Kaplan-Meier analyses of the TTP in the PR, SD and PD groups, as classified according to RECIST 1.1 (a) and the Choi criteria (b)Back to article page